NASDAQ:CRME Cardiome Pharma (CRME) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.30▼$2.4550-Day Range N/A52-Week Range$1.29▼$4.84Volume90,444 shsAverage Volume135,322 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial MediaProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media About Cardiome Pharma (NASDAQ:CRME) StockCardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.Read More Receive CRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiome Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CRME Stock News HeadlinesMarch 25, 2023 | marketwatch.comExpert Analysis on Pharmaceutical Rubber Stoppers Market by 2023-2030February 17, 2023 | msn.comGlenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mgJune 5, 2023 | Edge On The Street (Ad)Investor Alert: EV Initiatives Create Unsustainable Demand For LithiumThe soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.February 12, 2023 | msn.comPharmacy Career Conference returned in its 4th edition to assist and inspire pharmacy students and industry professionalsFebruary 1, 2023 | msn.comPharma sector growth healthy after Covid tooDecember 29, 2022 | cbsnews.comDOJ sues pharma giant AmerisourceBergen Corp. for allegedly helping to fuel the opioid epidemicNovember 2, 2022 | marketwatch.comAcute Coronary Syndrome Therapeutics Market Size in Pharma & Healthcare Sector is Growing Quickly with Analysis by Top Key players till 2028October 20, 2022 | yahoo.comPharmaceutical Fine Chemicals Category Is Projected to Grow at a CAGR of 5.86% by 2026, SpendEdge ReportsJune 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.October 13, 2022 | finance.yahoo.comJenny Sundqvist new CEO of InDex PharmaceuticalsSeptember 28, 2022 | benzinga.com1SOMAÍ Pharmaceuticals Opens Medical Cannabis Manufacturing Facility In PortugalSeptember 13, 2022 | msn.comNLEM 2022 | Govt releases new list of 384 essential medicines; 34 drugs added, 26 droppedSeptember 13, 2022 | msn.comMacleods Pharmaceuticals defers big-bang listing plans; will PE funds step in now?August 30, 2022 | marketwatch.comCardiac Rhythm Management Devices Market [4.5% CAGR] 2022 Industry Research Analysis Opportunities Key Players Analysis And Forecast By 2028October 26, 2021 | finance.yahoo.comCardiome Pharma Corp. Announces Approximately US$15.0 Million Bought Deal FinancingJune 21, 2020 | www.bloomberg.comCardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial ResultsJune 17, 2020 | www.bloomberg.comCardiome Announces Commercial Launch of Xydalba™ in Three New European GeographiesJune 2, 2020 | www.bloomberg.comCardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South AfricaMay 23, 2020 | www.bloomberg.comCardiome Reports Fourth Quarter and Full Year 2017 Financial ResultsMay 21, 2020 | www.bloomberg.comCardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA ResubmissionMarch 28, 2020 | www.bloomberg.comCorrevio Pharma Corp Completes Strategic Transaction with Cipher PharmaceuticalsFebruary 6, 2020 | finance.yahoo.comCanaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For SharesNovember 28, 2019 | www.thestreet.comCardiome Pharma Corp. (CRME): Today's Featured Health Care LoserSee More Headlines CRME Company Calendar Last Earnings5/15/2018Today6/05/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRME CUSIPN/A CIK1036141 Webwww.cardiome.com Phone604-677-6905FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Key ExecutivesDr. William L. Hunter (Age 55)Pres, CEO & Director Ms. Sheila M. Grant MBAChief Operating OfficerMr. David D. McMasters (Age 59)Gen. Counsel Mr. Hugues SachotChief Commercial OfficerMr. Justin A. Renz (Age 46)Chief Financial Officer Key CompetitorsCelyad OncologyNASDAQ:CYADLAVA TherapeuticsNASDAQ:LVTXNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSQilian International Holding GroupNASDAQ:QLIView All Competitors CRME Stock - Frequently Asked Questions How were Cardiome Pharma's earnings last quarter? Cardiome Pharma Corp (NASDAQ:CRME) issued its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million. What other stocks do shareholders of Cardiome Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiome Pharma investors own include Energy Transfer (ET), CBL & Associates Properties (CBL), Cornerstone Strategic Value Fund (CLM), Cornerstone Total Return Fund (CRF), SandRidge Permian Trust (PER), SunCoke Energy Partners (SXCP), Martin Midstream Partners (MMLP), Navios Maritime Midstream Partners (NAP), C3.ai (AI) and Government Properties Income Trust (GOV). What is Cardiome Pharma's stock symbol? Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME." What is Cardiome Pharma's stock price today? One share of CRME stock can currently be purchased for approximately $2.33. How can I contact Cardiome Pharma? Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The official website for the company is www.cardiome.com. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at ir@cardiome.com. This page (NASDAQ:CRME) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiome Pharma Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.